Findings in favor of treating COVID-19 infections with hydroxychloroquine (HCQ) + azithromycin (AZM)
-
In a French open-label non-randomized clinical trial, more patients treated with HCQ + AZM tested negative for COVID-19 by day 6 after inclusion in study
-
In vitro testing revealed synergistic effect of combined HCQ and AZM on SARS-CoV-2
-
A retrospective Detroit study using data from the Henry Ford Medical Group found that HCQ + AZM treatment was effective. However, this stipulates that the treatment is aggressive and giving patients dosages within 48 hr of patient admission as opposed to waiting.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Findings opposed to use of Azithromycin+Hydroxychloroquine as COVID-19 intervention
Findings in favor of treating COVID-19 infections with hydroxychloroquine (HCQ) + azithromycin (AZM)
Findings indicate no significant difference in comparison to standard care of treating COVID-19 infections with hydroxychloroquine + azithromycin
Learn After
In a French open-label non-randomized clinical trial, more patients treated with hydroxychloroquine+azithromycin tested negative for COVID-19 by day 6 after inclusion in study compared to a control group
In vitro testing revealed synergistic effect of combined hydroxychloroquine (HCQ) and azithromycin (AZM) on SARS-CoV-2
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19